Skip to main content
. 2015 Dec 9;7(3):3520–3532. doi: 10.18632/oncotarget.6513

Figure 3. RI-BPI changes the dynamic of the BCL2-family components and sensitizes cells to BH3 mimetic drugs.

Figure 3

A. Effect of RI-BPI on pro-survival BCL2-family members in the RI-BPI sensitive GCB-DLBCL OCI-Ly1 and OCI-Ly7 cells treated for 6 and 12 hours compared to their respective controls (full line, 0 h). Dotted line represents 2-fold expression increase. B. Effect on BCL2, BCL-XL and MCL1 protein levels in OCI-Ly1 and OCI-Ly7 cells after 48 h of exposure to RI-BPI. Densitometry values are shown at the bottom normalized to their respective controls. C. Fold drug reduction (expressed as dose reduction index) for ABT-737 (left) and obatoclax (right) in four RI-BPI sensitive and BH3-mimetic inhibitor resistant cell lines pre-treated for 48 h with RI-BPI. Dose reduction indexes smaller than 1 represent favorable combinations. D. Effect on BCL2, BCL-XL and MCL1 protein levels in SU-DHL8 cells after 48 h of exposure to RI-BPI. Densitometry values (RI-BPI/vehicle to actin) are shown on the right.